Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NAMPT (nicotinamide phosphoribosyltransferase)

Written2012-06Vassiliki Koumaki, Maria Dalamaga
Department of Microbiology, University of Athens, School of Medicine, University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece (VK); Department of Clinical Biochemistry, University of Athens, School of Medicine, Attikon General University Hospital, Rimini 1, Chaidari, 12462 Athens, Greece (MD)

(Note : for Links provided by Atlas : click)

Identity

Alias_namesPBEF1
pre-B-cell colony enhancing factor 1
Alias_symbol (synonym)PBEF
HGNC (Hugo) NAMPT
LocusID (NCBI) 10135
Atlas_Id 43890
Location 7q22.3  [Link to chromosome band 7q22]
Location_base_pair Starts at 105888732 and ends at 105925638 bp from pter ( according to hg19-Feb_2009)  [Mapping NAMPT.png]
Fusion genes
(updated 2016)
NAMPT (7q22.3) / CD69 (12p13.31)NAMPT (7q22.3) / NAMPT (7q22.3)NAMPT (7q22.3) / UBE2H (7q32.2)
NOP58 (2q33.1) / NAMPT (7q22.3)PLD5 (1q43) / NAMPT (7q22.3)ZBTB20 (3q13.31) / NAMPT (7q22.3)

DNA/RNA

 
  Genomic structure of NAMPT. Orange boxes indicate exons and purple boxes indicate untranslated regions.
Description The human NAMPT gene spans a length of 36908 bp. The NAPMT structural gene is composed of 11 exons and 10 introns.
Transcription Transcription produces 19 different mRNAs, 14 alternatively spliced variants and 5 unspliced forms. There are 5 probable alternative promoters, 6 non overlapping alternative last exons and 13 alternative polyadenylation sites. The mRNAs appear to differ by truncation of the 3' end, presence or absence of 2 cassette exons, overlapping exons with different boundaries, alternative splicing or retention of 4 introns (Zhang et al., 2011).
Pseudogene This gene has a pseudogene on chromosome 10 (provided by RefSeq 2011).

Protein

Description The reference human NAMPT protein sequence (NP_005737) consists of 491 amino acids.
Expression NAMPT is expressed in human heart, brain, placenta, lungs, liver, skeletal muscle, kidney and pancreas with the maximum amount in muscle tissue (Samal et al.,1994).
Localisation NAMPT is localized both in the nucleus and the cytosplasm (Kitani et al., 2003).
Function The three major functions of NAMPT: growth factor, cytokine and nicotinamide phosphoribosyltransferase. Accumulating evidence suggests that NAMPT can function as a growth factor or a cytokine though the underlying molecular mechanisms remain to be established. It is beyond any dispute that NAMPT can function as a nicotinamide phosphoribosyltransferase (Zhang et al., 2011).
Enzymatic activity: because of its pivotal role in the recycling pathway allowing NAD generation from nicotinamide, NAMPT occupies a central position in controlling the activity of several NAD-dependent enzymes (Gallí et al., 2010). NAD, a universal energy-and signal-carrying molecule and its phosphorylated form, NADP, are required in several intracellular processes such as redox reactions, DNA repair, G-protein coupled receptor signaling, intra-cellular calcium-mobilizing molecules, transcriptional regulation, mono-adenosine diphosphate (ADP)-ribosylation in immune response, and activity of poly-ADP ribosyltransferases and deacetylases (sirtuins) with roles in regulating cell survival and cytokine responses (Garten et al., 2009). Under the influence of NAMPT, adequate levels of NAD control SIRT-6 (sirtuin) activity, which in turn positively regulates TNF-α mRNA translation favoring cell survival (Gallí et al., 2010). NAMPT activity enhances cellular proliferation, tips the balance toward cellular survival following a genotoxic insult and controls the circadian clock machinery of some key transcriptions factors (Garten et al., 2009; Moschen et al., 2010).
Homology Significant sequence homology has been shared among prokaryotic organisms such as the bacterium Haemophilus ducreyi, primitive metazoan such as marine sponge, and humans (Martin et al., 2001). Amino acid sequence alignment revealed that the NAMPT gene is evolutionarily highly conserved, with the canine NAMPT protein sequence 96% identical to human NAMPT and 94% identical to both murine and rat PBEF counterparts (McGlothlin et al., 2005).

Mutations

Note Homozygous deletion confers embryonic lethality in mouse (Ye at al., 2005).
Up to June 2012 NCBI dbSNP reports 730 SNPs in the human NAMPT gene. Functional consequences of most of these SNPs are currently unknown (Zhang et al., 2011).
Acquired resistance to inhibitors of NAMPT has been associated with mutations of NAMPT located in the vicinity of the active site or in the dimer interface of NAMPT (Olesen et al., 2010).

Implicated in

Note
Entity Various diseases
Note The dysregulation of NAMPT gene as well as abnormalities in circulating NAMPT levels have been implicated in the susceptibility and pathogenesis of a number of human diseases and pathologic conditions given NAMPT's pleiotropic physiological functions. NAMPT has been implicated in cancer as described below, diabetes, obesity, aging, atherosclerosis, sepsis, acute lung injury, rheumatoid arthritis, etc (Zhang et al., 2011).
  
Entity Colorectal cancer (CC)
Note NAMPT expression was increased in primary colorectal cancer comparing to normal control mucosa using the suppression subtractive hybridization technique to identify new candidate genes in cancer (Hufton et al., 1999). This observation was later confirmed at tissue and protein level by Western blotting and immune-histochemical analyses (Van Beijnum et al., 2002). Serum Nampt levels were significantly higher in 115 CC patients than in 115 age-, gender- and body mass index (BMI)-matched controls both in univariate (p<0.01) and multivariable analyses (OR: 2.95, 95% C.I. 1.862-4.787, p<0.01) (Nakajima et al., 2010).
Prognosis Serum Nampt levels may represent a promising biomarker of CC malignant potential and stage progression. Circulating Nampt gradually increased with tumor stage progression (p<0.01) (Nakajima et al., 2010).
  
Entity Breast cancer (BC)
Note NAMPT is expressed in BC tissues, in MCF-7 BC cells and in doxorubicin-responsive BC (Folgueira et al., 2005; Gallí et al., 2010; Zhang et al., 2011; Moschen et al., 2010; Garten et al., 2009). Additionally, Nampt is present in bovine mammary epithelium, lactating mammary glands, and milk (Yonezawa et al., 2006). NAMPT stimulated the proliferation and DNA synthesis rate of MCF-7 human BC cells (Kim et al., 2010). More specifically, NAMPT upregulated mRNA levels of cyclin D1 and cdk2, well-known regulators for the G1-S progression (Kim et al., 2010). Circulating levels of Nampt were significantly elevated in women suffering from postmenopausal BC than in controls independently from known risk factors of BC, anthropometric and metabolic parameters as well as serum concentrations of leptin and adiponectin (Dalamaga et al., 2011). Stratification by BMI depicted that the association of serum Nampt with PBC risk was more pronounced among overweight/obese postmenopausal women after adjustment for the aforementioned parameters (Dalamaga et al., 2011; Dalamaga et al., 2012b).
Prognosis High NAMPT expression in BC tissues was reported to be associated with more malignant cancer behavior as well as adverse prognosis (Lee et al., 2011). In the high NAMPT expression group, the majority of patients were estrogen and progesterone negative (Lee et al., 2011). Serum Nampt could be used as potential diagnostic and prognostic biomarker in the armamentarium of BC monitoring and management. In postmenopausal women, circulating Nampt could provide additional information in conjunction with tumor markers CA 15-3 and carcinoembryonic antigen, particularly in discriminating early stage cases and estrogen/progesterone negative breast tumors (Dalamaga et al., 2012b). In multivariable regression analysis, the most significant predictors/determinants of serum Nampt levels were the hormone receptor status, the late stage of PBC and the lymph node involvement (Dalamaga et al., 2012b).
  
Entity Gastric cancer (GC)
Note Using real-time PCR and Western blotting, NAMPT was overexpressed at the mRNA and protein levels in gastric cancer cells and human gastric cancer tissues (Bi et al., 2011). The specific NAMPT inhibitor FK866 repressed gastric cancer cell proliferation in vitro (Bi et al., 2011). Serum Nampt levels were significantly higher in 156 GC patients than in 156 age- and gender-matched controls using multivariable analysis (p= 0.0013) (Nakajima et al., 2009).
Prognosis Nampt may be good biomarker of GC as its circulating levels gradually increased with stage progression (P<0.0001) (Nakajima et al., 2009).
  
Entity Prostate cancer (PC)
Oncogenesis In prostate carcinogenesis, NAMPT increased PC3 cell proliferation activating the mitogen-activated protein kinases (MAPKs) ERK-1/ERK-2 and p38 signaling pathways (Patel et al., 2010). NAMPT promoted the activity and expression of MMP-2/MMP-9 which represent important proteases involved in the breakdown of the extracellular matrix, indicating a possible role for NAMPT in PC metastasis (Patel et al., 2010). Upregulation of NAMPT expression occurs early in prostate neoplasia (Wang et al., 2011). Inhibition of NAMPT significantly suppresses cell growth in culture, soft agar colony formation, cell invasion and growth of xenografted prostate cancer cells in mice. NAMPT knockdown sensitizes prostate cancer cells to oxidative stress caused by H2O2 or chemotherapeutic treatment. Overexpression of NAMPT increases prostate cancer cell resistance to oxidative stress, which is partially blocked by SIRT1 knockdown (Wang et al., 2011).
  
Entity Brain tumors
Note Increased NAMPT expression was found in glioblastoma samples using cDNA microarray based expression profiling, real-time RT-qPCR and immunohistochemical staining on an independent set of brain tumor samples (Reddy et al., 2008). APO866, a NAMPT inhibitor, is a potent growth inhibitor against glioblastoma through targeting NAMPT. APO866 depleted intracellular NAD, caused marked inhibition of ERK activation and induced G2/M cell-cycle arrest in C6 glioblastoma cells (Zhang et al., 2012).
Prognosis Serum Nampt levels may be a potential serum biomarker for malignant astrocytoma and prognostic indicator in glioblastoma (Reddy et al., 2008).
  
Entity Ovarian cancer
Note NAMPT protein expression is significantly increased in ovarian serous adenocarcinoma comparing to benign ovarian tissue using tissue microarray and the avidin-biotin complex immuno-histochemical technique (Shackelford et al., 2010).
  
Entity Esophageal cancer
Prognosis Using quantitative one-step real time RT-PCR, circulating Nampt mRNAs in postoperative esophagectomy patients were upregulated adjusting for other factors (p<0.01) and were independent predictors of mortality in the first year of follow-up (Takahashi et al., 2010).
  
Entity Lymphoma
Note NAMPT expression was investigated in 53 samples of malignant lymphomas (diffuse large B-cell lymphoma, follicular B-cell lymphoma, Hodgkin's lymphoma and peripheral T-cell lymphoma). The expression of NAMPT was generally elevated in the more aggressive malignant lymphomas, with >80% strong expression, whereas the expression in the more indolent follicular lymphoma (FL) was significantly lower (>75% moderate or low expression, p= 0.0002) (Olesen et al., 2011). In Hodgkin's lymphoma, NAMPT was very highly expressed in Hodgkin Reed-Sternberg cells (Olesen et al., 2011).
  

Bibliography

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, Li HJ, Zhao W.
Oncol Rep. 2011 Nov;26(5):1251-7. doi: 10.3892/or.2011.1378. Epub 2011 Jul 4.
PMID 21743967
 
The role of adiponectin in cancer: a review of current evidence.
Dalamaga M, Diakopoulos KN, Mantzoros CS.
Endocr Rev. 2012b Aug;33(4):547-94. Epub 2012 Apr 30.
PMID 22547160
 
Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, Reis LF, Kaiano JH, Camargo LP, Vencio RZ, Snitcovsky IM, Makdissi FB, e Silva PJ, Goes JC, Brentani MM.
Clin Cancer Res. 2005 Oct 15;11(20):7434-43.
PMID 16243817
 
The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer.
Galli M, Van Gool F, Rongvaux A, Andris F, Leo O.
Cancer Res. 2010 Jan 1;70(1):8-11. Epub 2009 Dec 22. (REVIEW)
PMID 20028851
 
Nampt: linking NAD biology, metabolism and cancer.
Garten A, Petzold S, Korner A, Imai S, Kiess W.
Trends Endocrinol Metab. 2009 Apr;20(3):130-8. Epub 2008 Dec 26. (REVIEW)
PMID 19109034
 
A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization.
Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogenboom HR.
FEBS Lett. 1999 Dec 10;463(1-2):77-82.
PMID 10601642
 
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, Namgoong IS, Kim YI, Lee BJ.
Mol Cells. 2010 Oct;30(4):341-5. Epub 2010 Sep 10.
PMID 20848232
 
Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor.
Kitani T, Okuno S, Fujisawa H.
FEBS Lett. 2003 Jun 5;544(1-3):74-8.
PMID 12782293
 
High visfatin expression in breast cancer tissue is associated with poor survival.
Lee YC, Yang YH, Su JH, Chang HL, Hou MF, Yuan SS.
Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1892-901. Epub 2011 Jul 22.
PMID 21784959
 
Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence.
Martin PR, Shea RJ, Mulks MH.
J Bacteriol. 2001 Feb;183(4):1168-74.
PMID 11157928
 
Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor.
McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, Ma SF, Rumala BB, Garcia JG, Ye SQ.
Biochem Genet. 2005 Apr;43(3-4):127-41.
PMID 15934174
 
Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders.
Moschen AR, Gerner RR, Tilg H.
Curr Pharm Des. 2010 Jun;16(17):1913-20. (REVIEW)
PMID 20370672
 
Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y.
Cancer Sci. 2010 May;101(5):1286-91. Epub 2010 Jan 31.
PMID 20331631
 
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Olesen UH, Hastrup N, Sehested M.
APMIS. 2011 Apr;119(4-5):296-303. doi: 10.1111/j.1600-0463.2011.02733.x. Epub 2011 Mar 25.
PMID 21492230
 
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH, Petersen JG, Garten A, Kiess W, Yoshino J, Imai S, Christensen MK, Fristrup P, Thougaard AV, Bjorkling F, Jensen PB, Nielsen SJ, Sehested M.
BMC Cancer. 2010 Dec 12;10:677.
PMID 21144000
 
A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis.
Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, Randeva HS.
Peptides. 2010 Jan;31(1):51-7. Epub 2009 Oct 9.
PMID 19819277
 
PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value.
Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, Kondaiah P, Somasundaram K.
Cancer Biol Ther. 2008 May;7(5):663-8.
PMID 18728403
 
Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor.
Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I.
Mol Cell Biol. 1994 Feb;14(2):1431-7.
PMID 8289818
 
Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.
Shackelford RE, Bui MM, Coppola D, Hakam A.
Int J Clin Exp Pathol. 2010 Jun 12;3(5):522-7.
PMID 20606733
 
Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study.
Takahashi S, Miura N, Harada T, Wang Z, Wang X, Tsubokura H, Oshima Y, Hasegawa J, Inagaki Y, Shiota G.
J Transl Med. 2010 Oct 22;8:103.
PMID 20969744
 
Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer.
Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends JW, Hoogenboom HR, Hufton SE.
Int J Cancer. 2002 Sep 10;101(2):118-27.
PMID 12209988
 
Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.
Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG.
Microvasc Res. 2005 Nov;70(3):142-51. Epub 2005 Sep 26.
PMID 16188281
 
Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway.
Yonezawa T, Haga S, Kobayashi Y, Takahashi T, Obara Y.
FEBS Lett. 2006 Dec 11;580(28-29):6635-43. Epub 2006 Nov 15.
PMID 17123517
 
Nicotinamide Phosphoribosyltransferase in Human Diseases.
Zhang LQ, Heruth DP, Ye SQ.
J Bioanal Biomed. 2011 Jan 7;3:13-25.
PMID 22140607
 
Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, Wang F, Fang SH, Lu YB, Hu H, Wei EQ, Zhang WP.
Eur J Pharmacol. 2012 Jan 15;674(2-3):163-70. Epub 2011 Nov 19.
PMID 22119381
 

Citation

This paper should be referenced as such :
Koumaki, V ; Dalamaga, M
NAMPT (nicotinamide phosphoribosyltransferase)
Atlas Genet Cytogenet Oncol Haematol. 2012;16(12):909-912.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/NAMPTID43890ch7q22.html


External links

Nomenclature
HGNC (Hugo)NAMPT   30092
Cards
AtlasNAMPTID43890ch7q22
Entrez_Gene (NCBI)NAMPT  10135  nicotinamide phosphoribosyltransferase
Aliases1110035O14Rik; PBEF; PBEF1; VF; 
VISFATIN
GeneCards (Weizmann)NAMPT
Ensembl hg19 (Hinxton)ENSG00000105835 [Gene_View]  chr7:105888732-105925638 [Contig_View]  NAMPT [Vega]
Ensembl hg38 (Hinxton)ENSG00000105835 [Gene_View]  chr7:105888732-105925638 [Contig_View]  NAMPT [Vega]
ICGC DataPortalENSG00000105835
TCGA cBioPortalNAMPT
AceView (NCBI)NAMPT
Genatlas (Paris)NAMPT
WikiGenes10135
SOURCE (Princeton)NAMPT
Genetics Home Reference (NIH)NAMPT
Genomic and cartography
GoldenPath hg19 (UCSC)NAMPT  -     chr7:105888732-105925638 -  7q22.3   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)NAMPT  -     7q22.3   [Description]    (hg38-Dec_2013)
EnsemblNAMPT - 7q22.3 [CytoView hg19]  NAMPT - 7q22.3 [CytoView hg38]
Mapping of homologs : NCBINAMPT [Mapview hg19]  NAMPT [Mapview hg38]
OMIM608764   
Gene and transcription
Genbank (Entrez)AI299587 AK023341 AK292851 AK304085 AL832518
RefSeq transcript (Entrez)NM_005746 NM_182790
RefSeq genomic (Entrez)NC_000007 NC_018918 NT_007933 NW_004929332
Consensus coding sequences : CCDS (NCBI)NAMPT
Cluster EST : UnigeneHs.489615 [ NCBI ]
CGAP (NCI)Hs.489615
Alternative Splicing GalleryENSG00000105835
Gene ExpressionNAMPT [ NCBI-GEO ]   NAMPT [ EBI - ARRAY_EXPRESS ]   NAMPT [ SEEK ]   NAMPT [ MEM ]
Gene Expression Viewer (FireBrowse)NAMPT [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10135
GTEX Portal (Tissue expression)NAMPT
Protein : pattern, domain, 3D structure
UniProt/SwissProtP43490   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP43490  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP43490
Splice isoforms : SwissVarP43490
Catalytic activity : Enzyme2.4.2.12 [ Enzyme-Expasy ]   2.4.2.122.4.2.12 [ IntEnz-EBI ]   2.4.2.12 [ BRENDA ]   2.4.2.12 [ KEGG ]   
PhosPhoSitePlusP43490
Domains : Interpro (EBI)Nic_PRibTrfase-Fam    Nicotinamide_PRibTrfase    Quinolinate_PRibosylTrfase_C   
Domain families : Pfam (Sanger)NAPRTase (PF04095)   
Domain families : Pfam (NCBI)pfam04095   
Conserved Domain (NCBI)NAMPT
DMDM Disease mutations10135
Blocks (Seattle)NAMPT
PDB (SRS)2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
PDB (PDBSum)2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
PDB (IMB)2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
PDB (RSDB)2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
Structural Biology KnowledgeBase2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
SCOP (Structural Classification of Proteins)2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
CATH (Classification of proteins structures)2E5B    2E5C    2E5D    2GVG    2GVJ    3DGR    3DHD    3DHF    3DKJ    3DKL    4JNM    4JR5    4KFN    4KFO    4KFP    4L4L    4L4M    4LTS    4LV9    4LVA    4LVB    4LVD    4LVF    4LVG    4LWW    4M6P    4M6Q    4N9B    4N9C    4N9D    4N9E    4O0Z    4O10    4O12    4O13    4O14    4O15    4O16    4O17    4O18    4O19    4O1A    4O1B    4O1C    4O1D    4O28    4WQ6   
SuperfamilyP43490
Human Protein AtlasENSG00000105835
Peptide AtlasP43490
HPRD09938
IPIIPI00018873   IPI00922378   IPI00337370   IPI00853387   IPI00853449   
Protein Interaction databases
DIP (DOE-UCLA)P43490
IntAct (EBI)P43490
FunCoupENSG00000105835
BioGRIDNAMPT
STRING (EMBL)NAMPT
ZODIACNAMPT
Ontologies - Pathways
QuickGOP43490
Ontology : AmiGOnicotinate-nucleotide diphosphorylase (carboxylating) activity  cytokine activity  protein binding  extracellular space  nucleoplasm  cytosol  nicotinamide metabolic process  signal transduction  cell-cell signaling  female pregnancy  circadian rhythm  drug binding  positive regulation of cell proliferation  insulin receptor signaling pathway  NAD biosynthetic process  response to organic cyclic compound  cell junction  circadian regulation of gene expression  protein homodimerization activity  positive regulation of transcription from RNA polymerase II promoter  nicotinamide phosphoribosyltransferase activity  positive regulation of smooth muscle cell proliferation  positive regulation of nitric-oxide synthase biosynthetic process  adipose tissue development  extracellular exosome  
Ontology : EGO-EBInicotinate-nucleotide diphosphorylase (carboxylating) activity  cytokine activity  protein binding  extracellular space  nucleoplasm  cytosol  nicotinamide metabolic process  signal transduction  cell-cell signaling  female pregnancy  circadian rhythm  drug binding  positive regulation of cell proliferation  insulin receptor signaling pathway  NAD biosynthetic process  response to organic cyclic compound  cell junction  circadian regulation of gene expression  protein homodimerization activity  positive regulation of transcription from RNA polymerase II promoter  nicotinamide phosphoribosyltransferase activity  positive regulation of smooth muscle cell proliferation  positive regulation of nitric-oxide synthase biosynthetic process  adipose tissue development  extracellular exosome  
Pathways : KEGGNicotinate and nicotinamide metabolism   
REACTOMEP43490 [protein]
REACTOME PathwaysR-HSA-1368108 BMAL1:CLOCK,NPAS2 activates circadian gene expression [pathway]
REACTOME PathwaysR-HSA-197264 Nicotinamide salvaging [pathway]
NDEx NetworkNAMPT
Atlas of Cancer Signalling NetworkNAMPT
Wikipedia pathwaysNAMPT
Orthology - Evolution
OrthoDB10135
GeneTree (enSembl)ENSG00000105835
Phylogenetic Trees/Animal Genes : TreeFamNAMPT
HOVERGENP43490
HOGENOMP43490
Homologs : HomoloGeneNAMPT
Homology/Alignments : Family Browser (UCSC)NAMPT
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerNAMPT [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)NAMPT
dbVarNAMPT
ClinVarNAMPT
1000_GenomesNAMPT 
Exome Variant ServerNAMPT
ExAC (Exome Aggregation Consortium)NAMPT (select the gene name)
Genetic variants : HAPMAP10135
Genomic Variants (DGV)NAMPT [DGVbeta]
DECIPHER (Syndromes)7:105888732-105925638  ENSG00000105835
CONAN: Copy Number AnalysisNAMPT 
Mutations
ICGC Data PortalNAMPT 
TCGA Data PortalNAMPT 
Broad Tumor PortalNAMPT
OASIS PortalNAMPT [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICNAMPT  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDNAMPT
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch NAMPT
DgiDB (Drug Gene Interaction Database)NAMPT
DoCM (Curated mutations)NAMPT (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)NAMPT (select a term)
intoGenNAMPT
NCG5 (London)NAMPT
Cancer3DNAMPT(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM608764   
Orphanet
MedgenNAMPT
Genetic Testing Registry NAMPT
NextProtP43490 [Medical]
TSGene10135
GENETestsNAMPT
Huge Navigator NAMPT [HugePedia]
snp3D : Map Gene to Disease10135
BioCentury BCIQNAMPT
ClinGenNAMPT
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD10135
Chemical/Pharm GKB GenePA162396933
Clinical trialNAMPT
Miscellaneous
canSAR (ICR)NAMPT (select the gene name)
Probes
Litterature
PubMed361 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineNAMPT
EVEXNAMPT
GoPubMedNAMPT
iHOPNAMPT
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Jan 12 11:29:56 CET 2017

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.